Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on NOVARTIS AG
2016 Global Depression Drug Market – Forest Laboratories, AstraZeneca, Glaxo..
2016 NOVARTIS : lance un programme pour l’accès aux médicaments au Nigeria
2016 NOVARTIS' : Innovative Technology-Based Healthcare Program to Increase Availabil..
2016 NOVARTIS : launches SMS for Life 2.0 in Nigeria to help improve access to essent..
2016 NOVARTIS : provides update on pegpleranib Phase III clinical trial program in pa..
2016 NOVARTIS : Vodacom Launch ‘SMS for Life 2.0’ in Kaduna
2016 NOVARTIS : Fond farewell for Anne as she hands over helm
2016 NOVARTIS : PAKISTAN’S PHARMA INDUSTRY IS IMMATURE NEED PROMPT REFORM
2016 NOVARTIS : lança SMS for Life 2.0 na Nigéria para ajudar a melhorar o acesso a m..
2016 NOVARTIS : lance SMS for Life 2.0 au Nigeria pour aider à améliorer l’accè..
2016 NOVARTIS : launches SMS for Life 2.0 in Nigeria to help improve Access to Essent..
2016 NOVARTIS : launches SMS for Life 2.0 in Nigeria to help improve access to essent..
2016 NOVARTIS : launches SMS for Life 2.0 in Nigeria to help improve access to essent..
2016 NOVARTIS : provides update on pegpleranib Phase III clinical trial program in pa..
2016 NOVARTIS : Former Horsham Novartis site sold for 16m
2016 NOVARTIS' : Ultibro Breezhaler improved lung function and COPD symptoms after di..
2016 NOVARTIS : LEE011 (ribociclib) plus letrozole analyses show superior PFS across ..
2016 NOVARTIS : Bitter Taster Gene
2016 NOVARTIS : WLF Asks Court to Reject New Liability Theory that Would Drive Prescr..
2016 NOVARTIS : Patent Issued for Silicone Hydrogel Lens with a Crosslinked Hydrophil..
2016 NOVARTIS : Patent Issued for Wash Solution and Method for Affinity Chromatograph..
2016 NOVARTIS : Patent Issued for Systems and Methods for an Electrocapillary Positiv..
2016 NOVARTIS : David Epstein Joins as Special Advisor to Remedy Pharmaceuticals
2016 NOVARTIS : Patent Issued for Systems and Processes for Inserting an Intraocular ..
2016 NOVARTIS : Argentum and Alcon Settle Patent Dispute Over PAZEO®
2016 NOVARTIS : ' Ultibro® Breezhaler® improved lung function and COPD symptoms after..
2016 NOVARTIS : Ultibro Breezhaler Improved COPD Lung Function, Symptoms after Therap..
2016 NOVARTIS : announces Zykadia first-line study results showing 16.6 month progres..
2016 NOVARTIS : ' Lucentis® received EU approval in new indication - Lucentis the onl..
2016 NOVARTIS : GEMS school creates ‘World’s Largest Human Image of an Or..
2016 NOVARTIS : announces Zykadia® first-line study results showing 16.6 month progre..
2016 Une offre de Novartis sur Actelion jugée peu probable
2016 NOVARTIS : data shows Treatment-free Remission rates are consistently above 50% ..
2016 NOVARTIS : survey uncovers real-world burden of myeloproliferative neoplasms (ra..
2016 NOVARTIS : Selexys exit validates Oklahoma as place to start biotech firms
2016 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
2016 OXFORD BIOMEDICA : Notes Positive Novartis CTL019 Findings
2016 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
2016 NOVARTIS : plays down bid for biotech giant
2016 NOVARTIS : New interim data demonstrate Sandoz proposed biosimilar rituximab has..
2016 SCOTT MEACHAM : Selexys exit validates Oklahoma as place to start biotech firms
2016 NOVARTIS : presents results from first global registration trial of CTL019 in pe..
2016 NOVARTIS : presents results from first global registration trial of CTL019 in pe..
2016 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
2016 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
2016 Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer
2016 NOVARTIS : Patent Issued for Minimal Pulsation Ophthalmic Probe (USPTO 9498378)
2016 NOVARTIS : Access shares one-year learnings and announces memorandum of understa..
2016 NOVARTIS : Alcon Lensx Assigned Patent
2016 NOVARTIS : Payments to Healthcare Professionals
2016 NOVARTIS : Access shares one-year learnings and announces memorandum of understa..
2016 Actelion's ambitious independent-minded CEO will drive up takeover price
2016 Johnson & Johnson approaches Actelion about takeover deal
2016 J&J to make takeover approach for Actelion
2016 NOVARTIS : Pulmonologists, Novartis call for better care for women with COPD
2016 NOVARTIS : WaveTec Vision Systems Assigned Patent
2016 Lilly's drug for Alzheimer's fails big trial; shares drop
2016 MONOCLONAL ANTIBODIES MARKET 2016-20 : Celltrion, Boehringer Ingelheim, Dr Reddy..
2016 NOVARTIS : Patent Issued for Container for Accommodating an Ophthalmic Lens duri..
2016 Global Influenza Market - AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline,..
2016 NOVARTIS : Patent Issued for Bubble-Free Microfluidic Valve Systems and Methods ..
2016 NOVARTIS : New analysis of Novartis' Entresto® data shows long-term benefits on ..
2016 NOVARTIS : Patent Issued for Short Interfering Ribonucleic Acid (SiRNA) for Oral..
2016 ANIKA THERAPEUTICS : Global Hyaluronic Acid Market - Alcon, Inc., Allergan, Inc...
2016 NOVARTIS AG (NYSE : NVS) Acquires Selexys Pharmaceuticals Corp.
2016 NOVARTIS : Medication 'Quinax' excluded from state registration
2016 NOVARTIS : $14,539 Federal Contract Awarded to Alcon Laboratories
2016 NOVARTIS : acquires Selexys Pharmaceuticals in deal worth up to $ 665 million
2016 NOVARTIS : to acquire Selexys Pharmaceuticals for $665m
2016 NOVARTIS : acquires US pharma firm Selexys Pharmaceuticals
2016 GlaxoSmithKline seeks U.S. approval for triple lung drug
2016 NOVARTIS : acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for r..
2016 NOVARTIS : commends publication of major report which recommends broad use of du..
2016 Indian pharma companies missing on access to medicine index
2016 NOVARTIS : Innovative study with three treatment switches confirms Sandoz biosim..
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ($)
Sales 2016 48 745 M
EBIT 2016 11 760 M
Net income 2016 7 987 M
Debt 2016 15 019 M
Yield 2016 4,00%
P/E ratio 2016 20,59
P/E ratio 2017 19,61
EV / Sales 2016 4,11x
EV / Sales 2017 4,07x
Capitalization 185 489 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 79,7 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-3.71%185 489
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
MERCK & CO., INC.2.48%166 338
SANOFI-0.52%104 512
More Results